Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Verve Group

    MCap

    EUR684m

    Last close

    EUR3.67

    ▲ −0.04 (−1.08%)

    OSE Immunotherapeutics

    MCap

    EUR164m

    Last close

    EUR7.50

    ▲ 0.26 (3.59%)

    Amoeba

    MCap

    EUR27m

    Last close

    EUR0.52

    ▲ 0.04 (8.33%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oryzon Genomics (BME: ORY)

Last close As at 18/09/2024

EUR1.87

▲ −0.02 (−1.26%)

Market capitalisation

EUR122m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Flash note

Oryzon Genomics — First patient dosed in new AML combination study

Healthcare | Update

Oryzon Genomics — Multiple milestones anticipated in H224

Healthcare | Flash note

Oryzon Genomics — Strengthening vafidemstat’s IP profile

Healthcare | Flash note

Oryzon Genomics — Encouraging interim update on FRIDA
testalize-me-0jE8ynV4mis-unsplash
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net cash (€m)

19.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.3 (0.5) (9.5)
Relative 0.6 (5.8) (26.5)
52 week high/low €2.2/€1.6

Financials

Oryzon Genomics has announced the commencement of patient dosing in the investigator-initiated Phase Ib trial evaluating iadademstat as a combination treatment in first-line acute myeloid leukemia (AML). The study, which aims to recruit c 24 patients, is sponsored by Oregon Health & Science University (OHSU). It is designed to evaluate the safety, tolerability and optimal dose of iadademstat when administered alongside standard-of-care treatments venetoclax and azacitidine. It will also test for preliminary efficacy. Oryzon has previously generated encouraging results when investigating iadademstat in combination with azacitidine for newly diagnosed AML patients (ALICE trial) and this new study will explore potential further synergies of the broader combination.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 15.7 (5.3) (6.3) (7.49) N/A N/A
2023A 14.2 (4.4) (6.0) (5.65) N/A N/A
2024E 8.6 (4.1) (5.0) (4.99) N/A N/A
2025E 31.6 16.8 15.5 27.79 6.7 6.3

Research

Update

Healthcare

Oryzon Genomics — Multiple milestones anticipated in H224

Flash note

Healthcare

Oryzon Genomics — Strengthening vafidemstat’s IP profile

Healthcare

Flash note

Oryzon Genomics — First patient dosed in new AML combination study
View All

Further insights

insight

Epigenetics

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free